Patients Stopping Anti-Obesity Jabs Put On Weight at a Quadrupled Rate Than Dieters

A recent study suggests that patients who come off new GLP-1 drugs like Mounjaro or Wegovy may regain shed pounds much more quickly than those who end traditional lifestyle plans.

Research printed in a leading medical journal shows that while obese individuals often shed about a fifth of their body weight while on the medication, the weight returns at an average rate of nearly a kilo each month once they quit.

"Users purchasing these treatments need to be cognizant of the potential of rapid rebound weight gain when the treatment concludes," cautioned expert Dr. Susan Jebb.

That rate of regain means a return to original weight in about one and a half years.

Analyzing Therapies

The study, which reviewed dozens of trials involving thousands of participants, contrasted the effects of the injectable medications with older methods.

The team point out that individuals who lose weight through diet and exercise typically see a slower weight regain—approximately 100 grams monthly—once they finish.

Explaining the Rapid Rebound

Experts believe the way of the jabs explains the heightened weight return.

These medications copy a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.

"Artificially providing GLP-1 levels several times higher than the body's typical production could lead to the body to produce less of its own natural hormone, and could reduce responsiveness to its effects," explained Dr. Adam Collins, a nutrition researcher.

"Stopping of this medication results in appetite is uncontrolled, making binge eating far more likely."

A Chronic Issue?

Health authorities suggest the injections for people with obesity-related health risks, accompanied by prescribed lifestyle changes.

Professionals contend that, considering the significant potential of relapse, the treatment might need to be life-long.

This opinion is reinforced by drug manufacturers, who note that the results "underscore the long-term nature of excess weight," comparing it to managing diseases like hypertension.

Patient Experiences

Users who have discontinued the jabs describe a sudden return of appetite.

"It felt as if a switch flipping and you're instantly ravenous," recalled a patient.

This difficulty is worsened if users have not developed permanent lifestyle or habit modifications during treatment.

Significant Interest

Figures indicate that millions of adults in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.

• Adoption is more common among women than males.
• The middle-aged age group shows the greatest usage rates.
• A large proportion access the medications through private healthcare rather than public health services.

Ultimately, researchers stress that while these medications are potent agents for weight loss, they are not a permanent cure and long-term success hinges on combined lifestyle management.